BALDWIN BROTHERS LLC/MA - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 1 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BALDWIN BROTHERS LLC/MA ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2022$10,000
-52.4%
40,6040.0%0.00%
-66.7%
Q2 2022$21,000
-73.4%
40,604
+5.2%
0.00%
-62.5%
Q1 2022$79,000
-50.9%
38,6040.0%0.01%
-50.0%
Q4 2021$161,000
-55.2%
38,6040.0%0.02%
-60.0%
Q3 2021$359,000
-54.8%
38,604
-12.5%
0.04%
-54.0%
Q2 2021$795,00044,1160.09%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q4 2022
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 471,878$8,499,0006.04%
BALDWIN BROTHERS LLC/MA 44,116$795,0000.09%
DOWLING & YAHNKE LLC 15,806$285,0000.02%
INVERNESS COUNSEL LLC /NY/ 13,307$240,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 15,000$270,0000.01%
Cutler Group LLC / CA 4,200$75,0000.00%
MetLife Investment Management, LLC 10,805$194,5980.00%
HAP Trading, LLC 13,900$64,0000.00%
METROPOLITAN LIFE INSURANCE CO/NY 8,272$148,9790.00%
Ameritas Investment Partners, Inc. 1,867$34,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders